Clinical Trials | Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with Extensive-Stage Small Cell Lung Cancer that have had no prior systemic therapy. The purpose of this study is to determine what dose of the study drug, ivonescimab works best in combination with carboplatin and etoposide chemotherapy on your lung cancer. We will also examine the side effects, good and bad, associated with ivonescimab. In this study, you will be assigned to study treatment by randomization to receive either ivonescimab 10 mg/kg or 20 mg/kg. During the study treatment period, you will be asked to come to the hospital to receive the ivonescimab at the dose assigned during randomization with standard chemotherapy of carboplatin and etoposide during induction. You may or may not benefit as a result of your participation in this study. However, this study may also help doctors learn things that can help other people in the future. Once you are no longer receiving study drug, or if you decide to stop receiving the study treatment at any time, we will follow-up (either routine clinic visit or phone call) to see how you are doing and about any other anti-cancer therapies you may have taken or are taking. This will occur approximately every 2-4 months until the study closes (up to 3 years). Additional information found here: Study Details | NCT07057791 | Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer | ClinicalTrials.gov For questions, contact: [email protected]